 NEW YORK, Oct. 06, 2021 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association NYHA class II and class III chronic heart failure CHF with low ejection fraction HFrEF have been selected through peer review as a late breaking presentation at the American Heart Association AHA annual meeting occurring November 13th- 15th. The featured session is titled Building on the Foundations of Treatment: Advances in Heart Failure Therapy. 